Name: CJC-1295 + Ipamorelin 10mg
Brand: RetaLABS.is
SKU: cjc-1295-ipamorelin-10mg

Question 1

What is the CJC-1295 + Ipamorelin combination used for in research?

Accepted Answer

The CJC-1295 + Ipamorelin combination is researched for its synergistic effects on growth hormone secretion and downstream IGF-1 axis modulation. CJC-1295 is a GHRH analogue that activates growth hormone-releasing hormone receptors (GHRH-R) in the pituitary, amplifying the amplitude of endogenous GH pulses. Ipamorelin is a selective ghrelin mimetic that activates GH secretagogue receptor type 1a (GHS-R1a), increasing GH pulse frequency while demonstrating high selectivity, it does not significantly elevate cortisol, ACTH, or prolactin at research doses, unlike older ghrelin mimetics such as GHRP-2 or GHRP-6. Together, the two compounds stimulate GH release through distinct receptor pathways simultaneously, making the combination a widely cited model for studying GH pulse dynamics and IGF-1 axis modulation. The combination is particularly studied in models of age-related GH decline, where the dual pituitary stimulation protocol has shown augmented GH responses compared to either compound alone.

Question 2

How does CJC-1295 differ from Ipamorelin?

Accepted Answer

CJC-1295 is a modified GHRH (growth hormone-releasing hormone) analogue that acts on GHRH receptors in pituitary somatotrophs, amplifying the amplitude of GH secretory pulses (it increases how much GH is released per pulse. Ipamorelin is a synthetic pentapeptide ghrelin mimetic that acts on GHS-R1a (growth hormone secretagogue receptor type 1a), primarily increasing GH pulse frequency and lowering the threshold for GH release. These distinct receptor targets create a complementary interaction: CJC-1295 primes somatotroph cells and increases pulse size; Ipamorelin adds to pulse frequency through an independent receptor mechanism. The combination also allows researchers to study receptor pathway selectivity) CJC-1295's GHRH-R activation can be studied in isolation, then compared to combined GHRH-R + GHS-R1a activation with Ipamorelin added, enabling quantitative assessment of each receptor's contribution to the overall GH secretory response in a given research model.

Question 3

How should this blend be stored?

Accepted Answer

Store lyophilised CJC-1295 + Ipamorelin vials at −20°C, protected from light and moisture, until ready for reconstitution. Both peptides in the blend are stable in lyophilised form at −20°C for extended periods when the vial seal remains intact. Avoid cycling the vial between temperatures (even brief exposure to elevated temperatures prior to opening can introduce condensation that degrades the lyophilised powder). When ready to use, allow the vial to equilibrate to room temperature for a few minutes before opening to minimise condensation on the inside of the septum. Reconstitute with bacteriostatic water by injecting slowly along the vial wall and gently swirling. Once reconstituted, refrigerate at 2–8°C and use within four weeks. Do not freeze the reconstituted solution. Repeated freeze-thaw cycles of liquid peptide solutions promote aggregation in both the GHRH analogue (CJC-1295) and the cyclic ghrelin mimetic (Ipamorelin) components.

Question 4

Why is Ipamorelin considered selective?

Accepted Answer

Ipamorelin is characterised as selective in the research literature because it stimulates GH release with minimal off-target effects on other pituitary hormones (specifically ACTH, cortisol, and prolactin) compared to earlier GHS-R1a agonists like GHRP-2 and GHRP-6. This selectivity has been demonstrated in rat studies showing that Ipamorelin, unlike GHRP-2, does not significantly elevate plasma ACTH or corticosterone at doses that produce maximal GH stimulation. The mechanistic basis for this selectivity is thought to relate to the specific GHS-R1a binding profile and downstream signalling bias of Ipamorelin's cyclic pentapeptide structure compared to the hexapeptide GHRP compounds. For researchers, this selectivity is practically important: studies requiring isolated GH axis stimulation without confounding adrenal or stress hormone responses can use Ipamorelin as a clean GHS-R1a agonist, making it preferable to GHRP-2 or GHRP-6 in protocols where cortisol elevation would be a significant confounding variable.

CJC-1295 + Ipamorelin 10mg

Customer Reviews

Frequently Asked Questions

Research Guides